Wu Yuanbin, director of the Department of social development and science and technology of the Ministry of science and technology, said that at present, 11 new crown vaccines in China have entered the clinical research stage, of which three inactivated vaccines and one adenovirus vector vaccine have entered the phase III clinical trial. Other recombinant protein vaccines, mRNA vaccines and attenuated influenza virus vector vaccines are in phase I / II clinical trials. Four vaccines in phase III clinical trials are progressing smoothly. < p > < p > according to Yang Sheng, director of the Department of drug registration and administration of the State Food and drug administration, preclinical studies, phase I and phase II clinical studies should be completed before the vaccine is put on the market, and phase III clinical trials should be conducted to prove that the safety and effectiveness of the vaccine meet the set standards. In addition, commercial scale verification should be completed to prove the acceptable safety, clear effectiveness and quality controllability of the vaccine to be marketed. < / P > < p > the progress of phase III clinical trials is affected by many factors, such as the number of subjects, the number of groups of subjects and the results. Researchers will adopt the principle of special affairs to promote the launch of new coronavirus vaccine in China as soon as possible. According to Zeng Guang, chief epidemiologist of China Center for Disease Control and prevention, it is only nine months since the discovery of the new coronavirus. The exact protection time of each vaccine after vaccination needs long-term and large amount of research work. < / P > < p > at present, the serum monitoring results of the first vaccinated subjects in China show that the antibody level is still high, which suggests that the vaccine may have a long-term protective effect. According to Zheng Zhongwei, head of the vaccine research and development team of the scientific research group, the annual production capacity of new crown vaccine in China will reach more than 1 billion doses by next year. In the future, the vaccination will be arranged according to the high-risk population, high-risk population and general population. < / P > < p > ZHENG Zhongwei said that the new coronavirus vaccine will be priced according to the public product attributes. The pricing of new crown vaccine in China must be within the acceptable range of the public, and the guiding price of new crown vaccine will be put forward within the acceptable range of the public. The novel coronavirus pneumonia is a high risk factor for respiratory infectious diseases.
has also seen other respiratory infectious diseases such as influenza and adenovirus. No new crown vaccine is effective. In addition, for most people, the vaccine may not be available this winter or next spring.
therefore, novel coronavirus pneumonia and other respiratory infectious diseases, ventilation measures and autoimmune status should be used to decide whether to wear masks. In particular, some elderly people, patients with chronic diseases and children should be protected. In addition, it is suggested that people keep good habits such as wearing masks, washing hands frequently and keeping a distance. 08/16/2020